Mankind Pharma completes sale of Broadway Hospitality stake for ₹49 crore
NiveshIQ
NSE: MANKIND · Pharma
Mankind Pharma Ltd.
₹2,592.70▼ ₹25.20 (-0.96%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MANKIND. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Mankind Pharma Ltd.
Mankind Pharma Limited (MANKIND) is a leading Indian pharmaceutical company that develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company's key revenue drivers include its pharmaceutical products for acute and chronic therapeutics, as well as its consumer healthcare products such as condoms, pregnancy detection kits, and vitamin and mineral supplements. In its recent quarterly results, Mankind Pharma reported a 30% jump in PAT and crossed the Rs 14,000 crore revenue mark for FY26. The company has a diverse product portfolio and engages in various businesses including trading, exporting, and real estate. Mankind Pharma has a strong presence in the Indian market and has been expanding its international footprin
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10,260 Cr +15.60% | ₹12,207 Cr +19.00% | ₹14,278 Cr +17.00% |
| EBITDA Margin | 24.53% | 24.79% | 27.85% |
| Net Profit | ₹1,942 Cr +48.30% | ₹2,011 Cr +3.60% | ₹2,056 Cr +2.20% |
| EPS | ₹47.75 | ₹48.26 | ₹46.35 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Mankind Pharma Success Story: How 2 Brothers Built ₹1 Lakh Crore Empire From Zero
Mankind Pharma Ltd. Revenue Breakdown – NSE:MANKIND
🔒
+ 3 more stories about Mankind Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹3, 443 Cr, PAT ₹580 Cr, EPS ₹13.44, EBITDA margin 30.3%. Growth context: revenue YoY +11.8%, PAT YoY +36.4%, revenue QoQ -3.5%, PAT QoQ +40.0%. Street verdict: beat, revenue surprise -0.7%, PAT surprise +7.0%.
Management's focus on product launches, approvals, and therapy-mix improvement is expected to drive the next leg of grow...
FY26 (last completed FY): revenue ₹14, 278 Cr, PAT ₹2, 056 Cr, EBITDA margin 27.9%, EPS ₹46.35. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MANKIND
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MANKIND alongside your other holdings
Unlock full MANKIND research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Mankind Pharma Ltd.?
NiveshIQ detects active intelligence signals for Mankind Pharma Ltd. (MANKIND) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Mankind Pharma Ltd.?
Mankind Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹10,002,830.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.